26,927 findings
- Metabolic adaptationStrong
A form of Mfn2 lacking transmembrane domains stimulates glucose oxidation in mouse skeletal muscle.
This suggests that targeting Mfn2 could enhance glucose metabolism in muscle.
Supports 2013 - CellularStrong
ΔMfn2 enhances respiratory control ratio in mouse skeletal muscle.
This indicates potential for improving muscle energy efficiency.
Supports 2013 - Metabolic adaptationStrong
ΔMfn2 stimulates gluconeogenesis in mouse liver and hepatoma cells.
This suggests that manipulating Mfn2 could enhance glucose production in the liver.
Supports 2013 - MolecularStrong
Recreationally active males (RAM) demonstrated a 230% and 364% higher alpha3 and beta3 mRNA expression than recreationally active females (RAF), respectively.
Sex differences exist in Na+,K+-pump mRNA expression among recreationally active individuals.
Supports 2007 - CellularStrong
Semaglutide alleviated metabolic disorders, ameliorated myocardial fibrosis, improved cardiac function, antagonized oxidative stress, and suppressed cardiomyocyte apoptosis in diabetic mice.
Semaglutide may be beneficial for improving heart health in diabetic patients.
Supports 2024 - MolecularStrong
Semaglutide attenuated cardiac inflammation through restoring RKIP expression and inhibiting the TBK1-NF-κB pathway.
Understanding this mechanism can help in developing targeted therapies for cardiac inflammation in diabetes.
Supports 2024 - MolecularStrong
Semaglutide's anti-inflammatory effect is mediated through the Sirt3-dependent RKIP pathway, rather than glucose lowering.
This suggests that semaglutide may have benefits beyond just lowering blood sugar in diabetic patients.
Supports 2024 - NeuralStrong
Patients prescribed semaglutide or tirzepatide had an increased risk of nonarteritic anterior ischemic optic neuropathy (NAION) with a hazard ratio of 1.76.
Clinicians should monitor patients on semaglutide or tirzepatide for signs of NAION.
Supports 2025New - NeuralStrong
Patients prescribed semaglutide or tirzepatide had an increased risk of other optic nerve disorders with a hazard ratio of 1.65.
Clinicians should be aware of the risk of other optic nerve disorders in patients on semaglutide or tirzepatide.
Supports 2025New - Energy balanceStrong
No association was found with other disorders of the optic nerve or visual pathways.
Other optic nerve or visual pathway disorders are not linked to semaglutide or tirzepatide use.
Refutes 2025New - HormonalStrong
There were no significant changes in testosterone and insulin-like growth factor 1 levels after the resistance training program.
Resistance training may not significantly affect testosterone and IGF-1 levels in older women.
Refutes 2019 - NeuralStrong
Continuous positive airway pressure therapy is the most widely prescribed treatment for obstructive sleep apnea.
Clinicians should consider CPAP as a first-line treatment for patients with obstructive sleep apnea.
Supports 2024 - HormonalStrong
GIP antagonism has been shown to reduce the development of obesity in preclinical models.
GIP antagonism could be a potential strategy for obesity treatment.
Supports 2025New - Energy balanceStrong
There is a need to end disparities in cardiovascular morbidity and mortality related to race, sex, and income inequality.
Healthcare systems should implement strategies to reduce these disparities.
Supports 2023 - Energy balanceStrong
In monozygotic twin pairs, higher BMI was not associated with an increased risk of myocardial infarction (MI) or death.
Practitioners may consider that higher BMI in twins does not necessarily indicate a higher risk for MI or death.
Refutes 2016 - MolecularStrong
Fatty acids increase GDF15 levels dose dependently, with the greatest response observed with linolenic acid.
Incorporating fatty acids like linolenic acid may enhance GDF15 levels, potentially influencing dietary responses.
Supports 2023 - HormonalStrong
The effect of linolenic acid on food intake and body mass disappears in mice lacking the GDF15 receptor GFRAL.
The presence of the GFRAL receptor is essential for the appetite-suppressing effects of linolenic acid.
Supports 2023 - Energy balanceStrong
Semaglutide did not increase or reduce the risk of eye disorders (OR, 1.01; 95% CI, 0.91-1.12) or diabetic retinopathy (OR, 1.04; 95% CI, 0.92-1.17).
Semaglutide can be considered safe regarding eye disorders and diabetic retinopathy.
Refutes 2025New - Energy balanceStrong
The SMM/ICW ratio did not change in either the creatine or placebo group.
Creatine does not affect the ratio of intracellular water to muscle mass in resistance-trained individuals.
Refutes 2020 - Energy balanceStrong
Food and beverage industries' participation in health scientific events can lead to conflicts of interest.
Health professionals should be cautious of partnerships with food and beverage industries at scientific events.
Supports 2015 - Energy balanceStrong
Corporate sponsors significantly influence the scientific programs of health events.
Event organizers should be aware of the potential for corporate influence on scientific content.
Supports 2015 - Energy balanceStrong
There was no significant association between carbohydrate intake and mortality (p trend =0.69).
Carbohydrate intake may not be a significant factor in overall mortality for this demographic.
Refutes 2021 - CellularStrong
Whey and pea protein compared to water supplementation had no significant effects on post-exercise delayed onset of muscle soreness (DOMS) and fitness tests.
Protein supplementation may not significantly reduce muscle soreness or improve fitness performance after exercise.
Refutes 2020 - Energy balanceStrong
Regainers in the MedWeight study were older than maintainers.
Understanding age differences may help tailor weight loss strategies for different age groups.
Supports 2014